SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation announced today that MLL Munich Leukemia Laboratory (www.mll.com) has purchased Access Array™ and EP1™ Systems. The Access Array System is being used in combination with Roche’s 454 GS FLX and GS Junior sequencing instruments, enabling high-throughput targeted deep-resequencing analyses. The EP1 System is being used for rare mutation detection studies and minimal residual disease investigations.
